POMPANO BEACH, FL – January 2, 2013 - - Net Profits Ten Inc (OTC: FARE) is up 0.74% to $0.176 on a traded volume of 7.45million shares. In the last one year, the stock went up more than 21%. The 52-week range for the stock is $0.03 and $2.50.The stock opened at $0.18.
Will FOGC Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here http://csrnewsdaily.com/c1/?company=FARE
MedClean Technologies Inc(OTC: MCLN) is currently trading at $0.0001 on a traded volume of 5.47 million shares.In the last one year, the stock is down over 83%. The Company is engaged in the business of providing medical waste treatment solutions. MedCean designs, sells, and installs turnkey regulated medical waste solutions that are enough to be installed as a custom configuration at a customer location, delivered as a self-contained portable solution for specific applications.
How Should Investors Trade MCLN After The Recent Momentum, Find Out Here http://csrnewsdaily.com/c1/?company=MCLN
Strikeforce Technologies Inc(OTC: SFOR) is currently trading at $0.0025 on a traded volume of 1.11 million shares. Last month, the Company announcednew comprehensive Anti-Breach Cyber Security bundle. The Cyber Security bundle will proactively protect corporations from the top three most exploited vulnerabilities: remote network access, desktop data leakage & mobile devices.
Get Free Special Trend Analysis On SFOR Here http://csrnewsdaily.com/c1/?company=SFOR
mPhase Technologies Inc (OTC: XDSL) is currently trading at $0.0022on a traded volume of 2.64 million shares.The Company has been issued patent number 8,344,543 from the U.S. Patent & Trademark Office. The invention generally relates to a handheld, powered device containing at least one power module having at least one battery, wherein the power module is removable and separately connects to each of the load modules.
Get Free Special Trend Analysis On XDSL Here http://csrnewsdaily.com/c1/?company=XDSL
Advanced Cell Technology Inc (OTC: ACTC) surged up 4.13% to $0.058 on a traded volume of 1.38 million shares. Earlier, the Company announced the treatment of the fifth and sixth patients in the company’s European clinical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells, completing the second patient cohort. The patients were injected with 100,000 hESC-derived RPE cells as compared to 50,000 cells in the first cohort. The outpatient transplantation surgeries were performed successfully and the patients are recovering uneventfully.
Get Free Special Trend Analysis On ACTC Here http://csrnewsdaily.com/c1/?company=ACTC
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Pacific Dynasty Consultants Inc.
2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062